CLLS Cellectis S.A. Stock Quote

CLLS [NASD]

Index	-	P/E	-	EPS (ttm)	-1.88	Insider Own	-	Shs Outstand	42.49M	Perf Week	1.07%
Market Cap	1.37B	Forward P/E	-	EPS next Y	-2.33	Insider Trans	-	Shs Float	42.47M	Perf Month	13.22%
Income	-79.80M	PEG	-	EPS next Q	-0.78	Inst Own	38.90%	Short Float	1.84%	Perf Quarter	83.08%
Sales	72.20M	P/S	18.95	EPS this Y	-24.60%	Inst Trans	20.43%	Short Ratio	2.13	Perf Half Y	86.69%
Book/sh	6.83	P/B	4.58	EPS next Y	-29.40%	ROA	-4.70%	Target Price	35.10	Perf Year	88.49%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-7.20%	52W Range	7.32 - 34.71	Perf YTD	15.56%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-34.10%	52W High	-9.91%	Beta	2.53
Dividend %	-	Quick Ratio	6.00	Sales past 5Y	-2.80%	Gross Margin	-	52W Low	327.19%	ATR	2.42
Employees	205	Current Ratio	6.10	Sales Q/Q	-9.80%	Oper. Margin	-46.60%	RSI (14)	57.05	Volatility	5.41% 7.41%
Optionable	Yes	Debt/Eq	0.36	EPS Q/Q	-89.20%	Profit Margin	-31.10%	Rel Volume	0.68	Prev Close	31.62
Shortable	Yes	LT Debt/Eq	0.34	Earnings	-	Payout	-	Avg Volume	366.91K	Price	31.27
Recom	1.70	SMA20	5.40%	SMA50	17.53%	SMA200	61.14%	Volume	249,305	Change	-1.11%

Aug-19-20

Upgrade

Citigroup

Neutral → Buy

$15 → $32

May-12-20

Initiated

Robert W. Baird

Outperform

$20

Mar-06-20

Downgrade

Goldman

Neutral → Sell

$15 → $11

Oct-30-19

Resumed

Guggenheim

Buy

$28

Aug-09-19

Initiated

BTIG Research

Buy

$37

May-24-19

Resumed

Citigroup

Neutral

$22

Mar-14-19

Initiated

William Blair

Outperform

Dec-19-18

Initiated

Goldman

Neutral

Jul-16-18

Initiated

Barclays

Overweight

$50

Mar-16-18

Initiated

Guggenheim

Neutral

Sep-05-17

Reiterated

Wells Fargo

Outperform

$33 → $40

Sep-05-17

Downgrade

SunTrust

Buy → Hold

Mar-02-17

Initiated

Instinet

Buy

$49

Feb-28-17

Initiated

Wells Fargo

Outperform

Apr-05-16

Initiated

Ladenburg Thalmann

Buy

$45

Mar-02-16

Initiated

Sun Trust Rbsn Humphrey

Buy

Jul-20-15

Initiated

BofA/Merrill

Buy

$50

Apr-20-15

Initiated

Piper Jaffray

Overweight

$42

Apr-20-15

Initiated

Jefferies

Buy

$46

Jan-15-21 06:12PM	7 CRISPR Stocks for the Future of Medicine InvestorPlace
Jan-06-21 04:30PM	Monthly information on share capital and company voting rights GlobeNewswire
Dec-17-20 11:58AM	Cellectis (CLLS) Jumps: Stock Rises 9% Zacks
Dec-15-20 08:16PM	Cellectis Announces Withdrawal of Follow-On Offering GlobeNewswire -17.14%
07:52AM	The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga
Dec-14-20 04:19PM	Cellectis Announces Launch of Follow-On Offering GlobeNewswire +5.76%
Dec-08-20 04:30PM	Monthly information on share capital and company voting rights GlobeNewswire
Dec-07-20 10:42PM	Is CLLS A Good Stock To Buy Now? Insider Monkey
Dec-05-20 05:00PM	Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-18-20 07:29AM	The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted Benzinga +6.70%
Nov-17-20 08:00PM	FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis Product Candidate UCARTCS1 in Multiple Myeloma GlobeNewswire
Nov-16-20 04:30PM	Cellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer GlobeNewswire
Nov-06-20 04:30PM	Monthly information on share capital and company voting rights GlobeNewswire -5.90%
02:00PM	Cellectis SA (CLLS) Q3 2020 Earnings Call Transcript Motley Fool
12:15PM	Cellectis SA to Host Earnings Call ACCESSWIRE
Nov-05-20 04:35PM	Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020 GlobeNewswire +9.88%
Nov-04-20 09:18AM	American Society of Hematology (ASH) Abstract Shows Initial Anti-Leukemic Activity of UCART22 in BALLI-01 Phase 1 Study in R/R Adult B-ALL GlobeNewswire
Oct-21-20 04:30PM	Cellectis to Hold Third Quarter 2020 Earnings Call on Friday, November 6, 2020 at 8:00AM EST GlobeNewswire -5.53%
Oct-16-20 08:26AM	Calyxt Announces $15 Million Registered Direct Offering GlobeNewswire
Oct-13-20 09:45AM	The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher Zacks
Oct-07-20 04:30PM	Monthly information on share capital and company voting rights GlobeNewswire
Sep-07-20 04:30PM	Monthly information on share capital and company voting rights GlobeNewswire
Sep-02-20 04:56PM	Cellectis to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-05-20 04:30PM	Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2020 GlobeNewswire
Jul-29-20 04:30PM	Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDT GlobeNewswire
Jul-21-20 04:30PM	Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing GlobeNewswire
04:30PM	Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing GlobeNewswire
Jul-10-20 06:04PM	Monthly information on share capital and company voting rights GlobeNewswire
Jul-07-20 08:17AM	The Daily Biotech Pulse: Novavax Lands $1.6B For COVID-19 Vaccine, Amgen Prevails In Avastin Biosimilar Lawsuit, Cellectis Study Placed On Clinical Hold Benzinga -14.33%
Jul-06-20 05:19PM	To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxts Board of Directors GlobeNewswire
04:33PM	Cellectis Reports Clinical Hold Placed on MELANI-01 Study GlobeNewswire
Jul-05-20 10:28PM	Cellectis SA (CLLS): Hedge Funds Are Snapping Up Insider Monkey
Jun-30-20 11:30AM	Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year? Zacks
Jun-29-20 04:30PM	Cellectis S.A. Reports Results from Annual Shareholders General Meeting Held on June 29, 2020 GlobeNewswire
Jun-25-20 04:30PM	Cellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies GlobeNewswire
Jun-10-20 04:30PM	Monthly information on share capital and company voting rights GlobeNewswire
Jun-08-20 09:05AM	Moving Average Crossover Alert: Cellectis Zacks
Jun-03-20 11:30AM	Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year? Zacks -6.88%
Jun-01-20 07:56AM	Cellectis' Shares March Higher, Can It Continue? Zacks
May-18-20 04:30PM	Cellectis Appoints Biopharma Veteran Leopold Bertea as Senior Vice President of Technical Operations - Europe GlobeNewswire
May-13-20 09:08AM	How Cellectis (CLLS) Stock Stands Out in a Strong Industry Zacks -8.61%
May-12-20 04:30PM	Monthly information on share capital and company voting rights GlobeNewswire
10:02AM	Top Ranked Momentum Stocks to Buy for May 12th Zacks
May-11-20 04:30PM	Cellectis Annual Shareholders General Meeting to be Held on June 29, 2020 GlobeNewswire
May-09-20 02:00PM	Cellectis SA (CLLS) Q1 2020 Earnings Call Transcript Motley Fool
May-08-20 06:00AM	Cellectis S.A. (EPA:ALCLS) Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St.
May-06-20 04:30PM	Cellectis Provides Business Update and Reports Financial Results for First Quarter 2020 GlobeNewswire
Apr-30-20 06:13PM	Gilead, Takeda Rumored to Have Sights on Iovance GuruFocus.com -8.29%
Apr-29-20 04:30PM	Cellectis to Hold First Quarter 2020 Earnings Call on Thursday, May 7, 2020 at 7:30 AM EDT GlobeNewswire +7.64%
Apr-13-20 04:30PM	Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer GlobeNewswire +8.04%
Apr-10-20 05:00PM	Monthly information on share capital and company voting rights GlobeNewswire
Apr-02-20 12:00PM	What Makes Cellectis S.A. (CLLS) a New Strong Buy Stock Zacks
Mar-27-20 11:09AM	Cellectis Enters Oversold Territory Zacks
Mar-10-20 04:30PM	US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis Business Wire
Mar-06-20 04:30PM	Cellectis: Monthly Information on Share Capital and Company Voting Rights Business Wire -6.99%
Mar-04-20 04:30PM	Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results Business Wire
04:05PM	Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products Business Wire
Feb-25-20 04:30PM	Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST Business Wire
Feb-21-20 12:00PM	Cellectis S.A. (CLLS) Moves to Strong Buy: Rationale Behind the Upgrade Zacks
Feb-18-20 04:30PM	Cellectis and Servier Expand Collaboration on UCART19 Products Business Wire
Feb-07-20 05:00PM	Cellectis: Monthly Information on Share Capital and Company Voting Rights Business Wire
Jan-27-20 11:01PM	Imagine Owning Cellectis (EPA:ALCLS) And Wondering If The 43% Share Price Slide Is Justified Simply Wall St.
Jan-15-20 04:30PM	First Patient Dosed with Cellectis New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia Business Wire
Jan-13-20 04:15PM	Why This Biotech Stock Is Planning To Gene Edit Its Cancer Drugs Investor's Business Daily
Jan-09-20 04:30PM	Cellectis: Monthly Information on Share Capital and Company Voting Rights Business Wire
Jan-06-20 04:30PM	Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery Business Wire
Jan-02-20 09:16AM	Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day Zacks
Dec-31-19 08:45AM	3 Biotech Stocks Likely to Maintain Solid Momentum in 2020 Zacks
Dec-17-19 11:13AM	Gilead's Second CAR-T Treatment Suffers the Same Issues as Yescarta GuruFocus.com +15.28%
Dec-02-19 04:30PM	1st Patient Dosed with Cellectis Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Business Wire
Nov-21-19 07:22AM	The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
Nov-20-19 04:30PM	Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells Business Wire
Nov-13-19 04:30PM	Cellectis Publishes Creation of Smart CAR T-Cells for Potentially Safer, More Effective Treatments for Cancer in Nature Communications Business Wire
Nov-06-19 04:47PM	Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019 Business Wire
Oct-31-19 04:30PM	Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST Business Wire
Oct-30-19 01:15AM	We're Keeping An Eye On Cellectis's (EPA:ALCLS) Cash Burn Rate Simply Wall St. +7.54%
Oct-29-19 04:30PM	First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma Business Wire
Oct-04-19 01:02PM	2 Falling Knives Expected to Rebound GuruFocus.com
Oct-01-19 04:30PM	Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis Allogeneic UCART Product Candidates Business Wire +7.02%
Sep-15-19 04:23AM	Does Cellectis S.A. (EPA:ALCLS) Have A Particularly Volatile Share Price? Simply Wall St.
Aug-06-19 04:30PM	Cellectis Reports Financial Results for Second Quarter and First Six Months 2019 Business Wire
Jul-08-19 04:30PM	Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way Business Wire
Jun-26-19 04:30PM	Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019 Business Wire
May-07-19 04:32PM	Cellectis Reports Financial Results for First Quarter 2019 Business Wire
Apr-17-19 04:30PM	Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting Business Wire
Apr-03-19 08:19AM	The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings Benzinga
Apr-02-19 04:30PM	FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients Business Wire
Mar-11-19 04:10PM	Cellectis Reports 4th Quarter and Full Year 2018 Financial Results Business Wire
Mar-07-19 04:30PM	Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio Business Wire
02:47PM	5 Top Gene-Editing Stocks for 2019 Motley Fool
Feb-25-19 05:10PM	Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry Business Wire
Feb-07-19 07:25AM	Consolidated Research: 2019 Summary Expectations for Oceaneering International, Southwest Gas, WellCare Health Plans, Barnes & Noble, Cellectis S.A, and Payment Data Fundamental Analysis, Key Performance Indications GlobeNewswire
Dec-10-18 04:30PM	Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing Business Wire
Nov-13-18 04:30PM	Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018 Business Wire
Oct-17-18 08:10AM	New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Sep-19-18 04:30PM	CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board Business Wire
Sep-18-18 04:30PM	Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP Business Wire
Aug-20-18 07:40AM	Report: Exploring Fundamental Drivers Behind Ballard Power, Reading International, Odonate Therapeutics, Stitch Fix, Summit Therapeutics, and Cellectis S.A New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-02-18 04:30PM	Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer Business Wire
Aug-01-18 04:30PM	Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 Business Wire

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience